ICU Medical (NASDAQ:ICUI) VP Sells 5,417 Shares of Stock

Posted by Brian Himes on Aug 13th, 2026

ICU Medical, Inc. (NASDAQ:ICUI – Get Free Report) VP Daniel Woolson sold 5,417 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $181.33, for a total transaction of $982,264.61. Following the completion of the transaction, the vice president directly owned 17,062 shares of the company’s stock, valued at approximately $3,093,852.46. This trade represents a 24.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

ICU Medical Price Performance

ICU Medical stock traded up $3.77 during trading hours on Thursday, hitting $183.11. The stock had a trading volume of 186,244 shares, compared to its average volume of 296,462. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The stock has a market capitalization of $4.58 billion, a price-to-earnings ratio of 155.18, a PEG ratio of 2.54 and a beta of 0.74. ICU Medical, Inc. has a 1-year low of $111.42 and a 1-year high of $192.85. The stock’s fifty day moving average is $154.67 and its two-hundred day moving average is $141.46.

ICU Medical (NASDAQ:ICUI – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business had revenue of $547.88 million during the quarter, compared to analysts’ expectations of $533.44 million. During the same period last year, the company posted $2.10 EPS. The company’s revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, analysts predict that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ICUI has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Sanford C. Bernstein lowered shares of ICU Medical to a “market perform” rating in a report on Monday, June 15th. KeyCorp boosted their price objective on shares of ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research note on Tuesday, July 21st. Zacks Research downgraded ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $200.00 target price on shares of ICU Medical in a research report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, ICU Medical has a consensus rating of “Moderate Buy” and an average price target of $192.80.

Check Out Our Latest Report on ICU Medical

Hedge Funds Weigh In On ICU Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Emerald Investment Advisers LLC acquired a new position in shares of ICU Medical in the 2nd quarter valued at approximately $3,711,000. William Blair Investment Management LLC acquired a new stake in shares of ICU Medical during the second quarter worth approximately $25,242,000. Ieq Capital LLC acquired a new stake in shares of ICU Medical during the second quarter worth approximately $906,000. Allworth Financial LP bought a new stake in shares of ICU Medical in the second quarter worth $26,000. Finally, Madison Asset Management LLC bought a new stake in shares of ICU Medical in the second quarter worth $2,652,000. 96.10% of the stock is owned by hedge funds and other institutional investors.

About ICU Medical

(Get Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.